NextCure Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

NextCure wird ein Gewinn- und Umsatzwachstum von 5.6% bzw. 84.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 37.4% pro Jahr wachsen soll.

Wichtige Informationen

5.6%

Wachstumsrate der Gewinne

37.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	84.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

May 10

NextCure EPS misses by $0.01

May 06

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Feb 12

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

Jan 08

NextCure provides update on NC318 clinical program

Dec 17

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:NXTC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-44	-40	N/A	1
12/31/2025	N/A	-40	-33	N/A	3
12/31/2024	N/A	-54	-18	N/A	3
9/30/2024	N/A	-59	-45	-45	N/A
6/30/2024	N/A	-61	-46	-46	N/A
3/31/2024	N/A	-64	-51	-51	N/A
12/31/2023	N/A	-63	-54	-53	N/A
9/30/2023	N/A	-66	-53	-51	N/A
6/30/2023	N/A	-70	-55	-53	N/A
3/31/2023	N/A	-70	-55	-53	N/A
12/31/2022	N/A	-75	-56	-54	N/A
9/30/2022	N/A	-74	-61	-58	N/A
6/30/2022	N/A	-73	-58	-56	N/A
3/31/2022	N/A	-73	-61	-59	N/A
12/31/2021	N/A	-69	-60	-57	N/A
9/30/2021	N/A	-68	-53	-50	N/A
6/30/2021	N/A	-66	-57	-53	N/A
3/31/2021	N/A	-63	-55	-48	N/A
12/31/2020	22	-37	-52	-45	N/A
9/30/2020	24	-32	-56	-49	N/A
6/30/2020	26	-24	-47	-41	N/A
3/31/2020	27	-18	-43	-39	N/A
12/31/2019	6	-34	-39	-36	N/A
9/30/2019	4	-30	-8	-3	N/A
6/30/2019	3	-27	-4	0	N/A
3/31/2019	1	-24	2	6	N/A
12/31/2018	N/A	-23	5	8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NXTC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NXTC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NXTC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NXTC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: NXTC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NXTC in 3 Jahren voraussichtlich hoch sein wird

NextCure Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 25% to US$4.33

Price target decreased by 25% to US$4.33

Price target increased to US$6.67

Price target decreased to US$5.80

Price target decreased to US$6.25

Price target increased to US$14.14

Recent updates

Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

Insufficient new directors

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

New major risk - Revenue and earnings growth

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Nextcure, Inc. Provides Year-End Clinical Pipeline Updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605

NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Price target decreased by 25% to US$4.33

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

Price target decreased by 25% to US$4.33

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

Price target increased to US$6.67

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Price target decreased to US$5.80

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Price target decreased to US$6.25

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Price target increased to US$14.14

NextCure GAAP EPS of -$0.59

NextCure, Inc. Presents NC410 Data at the Extracellular Matrix Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

High number of new directors

Now 23% undervalued after recent price drop

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

NextCure, Inc. and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

Price target decreased to US$16.75

High number of new directors

Independent Director Xiaoxing Xu has left the company

NextCure: Large Upside With Downside Protected By Cash Pile

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell 2500 Growth Index

Nextcure and Collaborators Publish Preclinical Data on Novel Immunomedicine Nc410

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

NextCure EPS misses by $0.01

Independent Director has left the company

Full year 2020 earnings released: US$1.33 loss per share (vs US$2.15 loss in FY 2019)

Revenue behind estimates

NextCure, Inc. Announces Resignation of Briggs Morrison from the Board of Directors, Effective April 1, 2021

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

New 90-day high: US$13.64

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Nextcure, Inc

NextCure, Inc. Announces the Appointment of Han Myint as Chief Medical Officer

New 90-day high: US$13.07

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

NextCure, Inc. Provides Updates on NC318 Clinical Program

NextCure provides update on NC318 clinical program

Rosen Reminds Nextcure, Inc. Investors of Important November 20 Deadline in Securities Class Action

Earnings beat expectations

New 90-day high: US$11.65

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Against Nextcure Inc

Block & Leviton LLP Reminds Investors of Nextcure, Inc. for Violations of the Federal Securities Laws

Nextcure, Inc. Announces Resignation of Kevin N. Heller from Chief Medical Officer

Scott+Scott Attorneys At Law LLP Files Securities Class Action Against NextCure Inc